Description

This episode discusses patient priorities in primary biliary cholangitis.

The management of abnormal liver blood tests has traditionally been the focus of many clinicians and industry work in this area. However, it is known that some patients have a significant symptom burden, particularly from itch, cognitive symptoms, and fatigue. The community now recognises that both biochemical improvement and symptom management are of equal importance and this must be reflected in clinical practice and research agenda.

Faculty

• Jessica Dyson (Moderator)
• Alexander Artyomenko (IPSEN Representative)
• Stuart Kendrick (GSK Representative)
• Robert Mitchell-Thain (PBC Foundation Representative)
• Pam Vig (Mirum Pharmaceuticals Representative)

This episode was scheduled according to the international calendar for the Primary Biliary Cholangitis Awareness Month.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

This EASL Studio is supported by CymaBay Therapeutics, GSK, IPSEN, and Mirum Pharmaceuticals.

Description

In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases.

Faculty 

• Aleksander Krag (Moderator)
• Juan Pablo Arab (Faculty)
• Alexandre Louvet (Faculty)
• Maru Rinella (Faculty)

Related episodes:

• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S3E5: JHEP Live: Stigma and alcohol

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Join the faculty as they take a deep dive into hepatitis delta (HDV) to:

• Shed light on the controversies surrounding this disease.
• Share their perspectives on the latest and most hotly debated recommendations.
• Discuss how these new recommendations will shape the future of research and patient care.

Faculty

• Thomas Berg (Moderator)
• Maurizia Brunetto (Faculty)
• Ohad Etzion (Faculty)

Related episodes:

• EASL Studio S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor
• EASL Studio S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). HEV infections are among the most common causes of acute hepatitis worldwide.

2 different settings:

• HEV genotypes 1 and 2 cause primarily in water-born outbreaks inn resource-limited settings
• HEV genotypes 3 and 4 have emerged as porcine zoonoses in middle and high-income areas, including Europe

This Studio focuses on Zoonotic Hep E, especially HEV Genotype 3 infection and discusses recent highlights as well as current challenges in basic, translational, and clinical research on Hepatitis E.

Learn more about the viral and host determinants for the diverse clinical outcomes of HEV genotype 3 infections, the challenge of chronic Hepatitis E in immunocompromised patients, as well as the current state of vaccine development and other preventive measures.

Faculty

• Darius Moradpour (Moderator)
• Patrick Behrendt (Faculty)
• Montserrat Fraga Christinet (Faculty)
• Eike Steinmann (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In the first episode of EASL Studio season 4, the faculty looked at the current status of hepatitis B elimination and discussed what needs to be done to achieve it.

Faculty

• Dr Ahmed Elsharkawy (Moderator)
• Mr Danjuma K. Adda (Faculty)
• Prof. Maud Lemoine (Faculty)
• Prof. Jean-Michel Pawlotsky (Faculty)
• Dr John Ward (Faculty)

Related episodes

• Special Edition: Live from Viral Hepatitis Elimination Conference 2022
• S3E2: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor
• S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition

ℹ️ Please click here to access the podcast version of this EASL Studio episode.